Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
foresitecapital.com

See what CB Insights has to offer

Investments

132

Portfolio Exits

44

Funds

11

Partners & Customers

1

Service Providers

1

About Foresite Capital

Foresite Capital is a multi-stage healthcare and life sciences investment firm that applies rigorous scientific and data-driven approaches to investment analysis. The firm has $2.2 billion in assets under management. Foresite Capital takes a collaborative approach to investing with its portfolio companies by providing a multidisciplinary team of scientists, engineers, analysts, and clinicians who understand the unique business models in healthcare in addition to capital. The company aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles. Its portfolio also emphasizes companies that are employing the tools of data science and machine intelligence in healthcare. Foresite Capital is based in San Francisco with an office in New York.

Foresite Capital Headquarter Location

600 Montgomery Street Suite 4500

San Francisco, California, 94111,

United States

415-877-4887

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Foresite Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Foresite Capital in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Foresite Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Foresite Capital Rank

Research containing Foresite Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Foresite Capital in 2 CB Insights research briefs, most recently on Oct 8, 2020.

Foresite Capital Investments

132 Investments

Foresite Capital has made 132 investments. Their latest investment was in DNAnexus as part of their Series I on March 3, 2022.

CBI Logo

Foresite Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/8/2022

Series I

DNAnexus

$200M

No

16

1/27/2022

Series A

TenSixteen Bio

$30M

No

2

1/20/2022

Series B

ImmPACT Bio

$111M

Yes

15

1/10/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/6/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/8/2022

1/27/2022

1/20/2022

1/10/2022

1/6/2022

Round

Series I

Series A

Series B

Series C

Series B

Company

DNAnexus

TenSixteen Bio

ImmPACT Bio

Subscribe to see more

Subscribe to see more

Amount

$200M

$30M

$111M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

16

2

15

10

10

Foresite Capital Portfolio Exits

44 Portfolio Exits

Foresite Capital has 44 portfolio exits. Their latest portfolio exit was Ivantis on November 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/8/2021

Acquired

$99M

5

10/7/2021

IPO

11

9/24/2021

IPO

$99M

21

8/6/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/17/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/8/2021

10/7/2021

9/24/2021

8/6/2021

6/17/2021

Exit

Acquired

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

11

21

10

10

Foresite Capital Fund History

11 Fund Histories

Foresite Capital has 11 funds, including Foresite Capital Opportunity Fund V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/3/2022

Foresite Capital Opportunity Fund V

$173M

3

2/25/2021

Foresite Capital Fund V

$400M

3

5/3/2018

Foresite Capital Fund IV

Multi-Stage Venture Capital

Closed

$668M

1

7/29/2015

Foresite Capital Fund III

Subscribe to see more

Subscribe to see more

$99M

10

4/1/2014

Foresite Capital Fund II

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/3/2022

2/25/2021

5/3/2018

7/29/2015

4/1/2014

Fund

Foresite Capital Opportunity Fund V

Foresite Capital Fund V

Foresite Capital Fund IV

Foresite Capital Fund III

Foresite Capital Fund II

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$173M

$400M

$668M

$99M

$99M

Sources

3

3

1

10

10

Foresite Capital Partners & Customers

1 Partners and customers

Foresite Capital has 1 strategic partners and customers. Foresite Capital recently partnered with En Pointe Technologies on .

Date

Type

Business Partner

Country

News Snippet

Sources

Partner

United States

Press Release – En Pointe and Foresite Announce Strategic Partnership.

Foresite , a provider of threat mitigation and managed security services , today announced that they have partnered with En Pointe Technologies to deliver threat mitigation and managed security services to their customers many of whom are facing unprecedented information security challenges and increasingly complex compliance regulations .

1

Date

Type

Partner

Business Partner

Country

United States

News Snippet

Press Release – En Pointe and Foresite Announce Strategic Partnership.

Foresite , a provider of threat mitigation and managed security services , today announced that they have partnered with En Pointe Technologies to deliver threat mitigation and managed security services to their customers many of whom are facing unprecedented information security challenges and increasingly complex compliance regulations .

Sources

1

Foresite Capital Service Providers

1 Service Provider

Foresite Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Foresite Capital Team

7 Team Members

Foresite Capital has 7 team members, including current Founder, Chief Executive Officer, Jim Tananbaum.

Name

Work History

Title

Status

Jim Tananbaum

Prospect Venture Partners, Theravance Biopharma, Sierra Ventures, and Merck & Co.

Founder, Chief Executive Officer

Current

Dennis Ryan

FS Development, and Lighthouse Capital Partners

Chief Financial Officer, Managing Director

Current

Vikram Bajaj

Managing Director

Current

Alisa Mall

Carnegie Corporation of New York, Tishman Speyer Properties, and Orrick

Managing Director

Current

Michael Rome

Dafna Capital Management, Vault Pharma, Caltech, and UCLA

Managing Director

Current

Name

Jim Tananbaum

Dennis Ryan

Vikram Bajaj

Alisa Mall

Michael Rome

Work History

Prospect Venture Partners, Theravance Biopharma, Sierra Ventures, and Merck & Co.

FS Development, and Lighthouse Capital Partners

Carnegie Corporation of New York, Tishman Speyer Properties, and Orrick

Dafna Capital Management, Vault Pharma, Caltech, and UCLA

Title

Founder, Chief Executive Officer

Chief Financial Officer, Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.